Cargando...
Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
Breast cancers (BC) associated with germline mutations of BRCA1/2 represent 3–5% of cases. BRCA1/2-associated BC have biological features leading to genomic instability and potential sensitivity to DNA damaging agents, including poly(ADP-ribose) polymerase (PARP) and platinum agents. In this review,...
Guardado en:
| Publicado en: | Cancers (Basel) |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6316565/ https://ncbi.nlm.nih.gov/pubmed/30544963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10120506 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|